Transdermal drug delivery in vitro using diffusion cells

Current Medicinal Chemistry

Volumn 19, Issue 27, 2012, Pages 4671-4677

  Bartosova, L ^a,b   Bajgar, J ^a,c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

Author keywords

Absorption; Dermal; Diffusion cell; Franz cell; In vitro; Penetration; Percutaneous; Permeation; Skin; Transdermal delivery

Indexed keywords

RECEPTOR; DRUG; DRUG CARRIER;

ARTICLE; DIFFUSION; DRUG ABSORPTION; DRUG EXPOSURE; HUMAN; IN VITRO STUDY; LIQUID; MATHEMATICAL ANALYSIS; NONHUMAN; SAMPLING; SKIN ABSORPTION; SKIN FUNCTION; SKIN STRUCTURE; STORAGE; TIME; TRANSDERMAL DRUG ADMINISTRATION; ANIMAL; ANIMAL MODEL; CHEMISTRY; METABOLISM; PERMEABILITY; REVIEW; SKIN;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; MODELS, ANIMAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION;

EID: 84875237454     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803306358     Document Type: Article

References (70)

1. Barry, B.W. In: Dermatological Formulations. Drugs and the Pharmaceutical Sciences. Percutaneous Absorption. Swarbrick, J., Ed.; Marcel Dekker: New York, 1983; vol. 18, pp. 95-116.
2. Prausnitz, M.R.; Langer, R. Transdermal drug delivery. Nat. Biotechnol., 2008, 26(11), 1261-1268.
3. Akomeah, F.K.; Martin, G.P., Brown, M.C. Variability in human skin permeability in vitro: comparing penetrants with different physicochemical properties. J. Pharm. Sci., 2007, 96(4), 824-834.
4. Poet, T.S.; McDougal, J.N. Skin absorption and human risk assessment. Chem. Biol. Interact., 2002, 140(1), 19-34.
5. Baert, B.; De Spiegeleer, B. Quality analytics of Internet pharmaceuticals. Anal. Bioanal. Chem,. 2010, 398(1), 125-36.
6. OECD: OECD guideline for the testing of chemicals. Skin absorption: in vitro method. Giudeline 428. Adopted April 2004, pp. 1-8.
7. OECD: Guidance document for the conduct of skin absorption studies. Organisation for Economic Co-operation and Development, Environment Directorate. OECD Environmental Health and Safety Publication Series on Testing and Assessment No. 28; ENV/JM/MONO(2004)2; March 2004; pp. 1-31.
8. Bouwstra, J.A; Honeywell-Nguyen, P.L. Skin structure and mode of action of vesicles. Adv. Drug Deliv. Rev., 2002, 54(Suppl. 1), S41-55.
9. Bouwstra, J.A.; Honeywell-Nguyen, P.L.; Gooris, G.S; Ponec, M. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res., 2003, 42(1), 1-36.
10. Flynn, G.L. In: Percutaneous absorption ; mechanisms-methodology-drug delivery; Bronough, R. and Maibach, H.I., Eds.; Marcel Dekker: New York, 1985; pp. 17-42.
11. WHO (World Health Organisation) Kielhorn, J.; Melching-Kollmuss, S.; Mangelsdorf, I. Dermal Absorption. WHO/IPCS Environmental Health Criteria. Draft February 2005. http://www.who.int/ipcs/publications/ehc/ehc235.pdf (Accessed February 3, 2012).
12. Wester, R.C.; Maibach, H.I. In: Transdermal Delivery of Drugs, Kydonieus, A.F. and Berner, B., Eds.; CRC Press: Boca Raton, 1987; Vol. 1, pp. 61-70.
13. Sato, K.; Sugibayashi, K.; Morimoto, Y. Species differences in percutaneous absorption of nicorandil. J. Pharm. Sci., 1991, 80(2), 104-107.
14. Tiemessen, H. In: Dermal and transdermal drug delivery; Gurny, R. and Teubner, A., Eds.; Wissenschaftliche Verlagsgesellshaft mbH: Stuttgart, 1993, pp. 101-117.
15. Barber, E.D.; Teetsel, N.M.; Kolberg, K.F.; Guest, D. A comparative study of the rates of in vitro percutaneous absorption of eight chemicals using rat and human skin. Fundam. Appl. Toxicol., 1992, 19(4), 493-497.
16. Van de Sandt, J.J.; Meuling, W.J.; Elliott, G.R.; Cnubben, N.H.; Hakkert, B.C. Comparative in vitro-in vivo percutaneous absorption of the pesticide propoxur. Toxicol. Sci., 2000, 58(1), 15-22.
17. European Commission. Scientific Committee on Consumer Products (SCCP). Opinion on basic criteria for the in vitro assessment of dermal absorption of cosmetic ingredients. SCCP 0970/06. Adopted March 2006.
18. Ackermann, K., Borgia, S.L., Korting, H.C., Mewes, K.R., Schäfer-Korting, M. The Phenion full-thickness skin model for percutaneous absorption testing. Skin Pharmacol. Physiol., 2010, 23(2), 105-112.
19. Bouwstra, J.A.; Groenink, H.W.; Kempenaar, J.A.; Romeijn, S.G.; Ponec, M. Water distribution and natural moisturizer factor content in human skin equivalents are regulated by environmental relative humidity. J. Invest. Dermatol., 2008, 128(2), 378-88.
20. Godin, B., Touitou, E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv. Drug Deliv. Rev., 2007, 59(11), 1152-1161.
21. Wilkinson, S.C. In: Principles and Practice Skin Toxicology; Chilcott, R.P. and Price, S., Eds.; John Wiley & Sons: Chichester, 2008; pp. 69-82.
22. Schaefer, H.; Redelmeier, T.E. In: Skin Barrier: Principles of Percutaneous Absorption. Schaefer, H. and Redelmeier, T.E., Eds.; Karger: Basel, 1996; pp. 56-59.
23. Lauer, A.C. In: Percutaneous Absorption: drugs-cosmetics-mechanisms-methodology. Bronough, R. and Maibach, H.I., Eds.; Marcel Dekker: New York, 1999; pp. 427-449.
24. Michniak-Kohn, B.B.; Wertz, P.W.; Al-Khalili, M.; Meidan, V.M. In. Delivery system handbook for personal care and cosmetic products: technology, applications and formulations. Rosen, M.R., Ed.; William Andrew: New York, 2005; pp. 77-100.
25. Pugh, J.W.; Chilcott, R.P. In: Principles and Practice Skin Toxicology; Chilcott, R.P. and Price, S., Eds.; John Wiley & Sons: Chichester, 2008; pp. 93-106.
26. Riviere, J.E. In. Human Exposure to Pollutants Via Dermal Absorption and Inhalation. Lazaridis, M. and Colbeck, I., Eds,; Springer: Dordrecht, 2009; pp. 237-251.
27. EC (European Commission). Guidance Document on Dermal Absorption. Draft March 2004. http://ec.europa.eu/food/plant/protection/evaluation/guidance/wrkdoc20-rev-en.pdf (Accessed February 3, 2012).
28. Fedors, R.F. Method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci., 1974, 14, 147-154.
29. Patel, H.; Berge, W.T.; Cronin, M.T.D. Quantitative structure-activity relationships (QSARs) for the prediction of skin permeation of exogenous chemicals. Chemosphere, 2002, 48(6), 603-613.
30. Magnusson, B.M.; Anissimov, Y.G.; Cross, S.E.; Roberts, M.S. Molecular size as the main determinant of solute maximum flux across the skin. J. Invest. Dermatol., 2004, 122(4), 993-999.
31. Bos, J.D.; Meinardi, M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol., 2000, 9(3), 165-169.
32. Brain, K.R.; Chilcott, R.P. In: Principles and Practice Skin Toxicology; Chilcott, R.P. and Price, S., Eds.; John Wiley & Sons: Chichester, 2008; pp. 83-92.
33. Vecchia, B.E.; Bunge, A.L. In: Transdermal drug delivery; Guy, R. and Hadgraft, J., Eds.; Marcel Dekker: New York, 2003; pp. 57-141.
34. United States Environmental Protection Agency (USEPA). Dermal Exposure Assessment: Principles and Applications. EPA/600/8-91/011B. January 1992.
35. Pannatier, A.; Jenner, P.; Testa, B.; Etter, J.C. The skin as a drugmetabolizing organ. Drug Metab. Rev., 1978, 8(2), 319-343.
36. Kao, J.; Carver, M.P. Cutaneous metabolism of xenobiotics. Drug Metab. Rev., 1990, 22(4), 363-410.
37. Hotchkiss, S.A.M. In: Dermal Absorption and Toxicity Assessment. Roberts, M.S. and Walter, K.A., Eds.; Marcel Dekker Inc.: New York, 1998; pp. 43-101.
38. Hewitt, P.G.; Perkins, J.; Hotchkiss, S.A. Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. II: in rat skin homogenates. Drug Metab. Dispos., 2000, 28(7), 755-759.
39. van Ravenzwaay, B.; Leibold, E. A comparison between in vitro rat and human and in vivo rat skin absorption studies. Hum. Exp. Toxicol., 2004, 23(9), 421-430.
40. Beck, H.; Bracher, M.; Bartnik, F.G. Percutaneous absorption of hair dyes: an interlaboratory comparison of in vivo and in vitro data with rat and pig. In vitro Toxicol., 1994, 7(4), 305-312.
41. Van de Sandt J.J.; Van Burgsteden, J.A.; Cage, S.; Carmichael, P.L.; Dick, I.; Kenyon, S.; Korinth, G.; Larese, F.; Limasset, J.C.; Maas, W.J.; Montomoli, L.; Nielsen, J.B.; Payan, J.P.; Robinson, E.; Sartorelli, P.; Schaller, K.H.; Wilkinson, S.C.; Williams, F.M. In vitro predictions of skin absorption of caffeine, testosterone, and benzoic acid: a multi-centre comparison study. Regul. Toxicol. Pharmacol., 2004, 39(3), 271-281.
42. Beck, H.; Brain, K., Grabarz, R., Green, D., Howes, D.; Kitchiner, L.; Pendlington, R., Python, M.; Schröder, Sharma, R., Steiling, W., Sugimoto, K.; Walters, K. In: Perspectives in Percutaneous Absorption. Brain, K.R. and Walters K.A., Eds.; STS Publishing: Cardiff, 2000; p. 27.
43. Franz, T.J. Percutaneous absorption on the relevance of in vitro data. J. Invest. Dermatol., 1975, 64(3), 190-195.
44. Bronaugh, R.L.; Stewart, R.F. Methods for in vitro percutaneous absorption studies IV: The flow-through diffusion cell. J. Pharm. Sci., 1985, 74(1), 64-67.
45. Pendlington, R.U. In: Principles and Practice Skin Toxicology; Chilcott, R.P. and Price, S., Eds.; John Wiley & Sons: Chichester, 2008; pp. 129-147.
46. Brain, K.R.; Walters, K.A.; Watkinson, A.C. In: Dermal Absorption and Toxicity Assessment. Roberts, M.S. and Walter, K.A., Eds.; Marcel Dekker Inc.: New York, 1998; pp. 161-187.
47. Bodé, S.; Baert, B.; Vangele, M.; Lambert, J.; Burvenich, C.; Slegers, G.; De Spiegeleer, B. Stability of the OECD model compound benzoic acid in receptor fluids of Franz diffusion cells. Pharmazie, 2007, 62(6), 470-1.
48. Baert, B.; Boonen, J.; Burvenich, C.; Roche, N.; Stillaert, F.; Blondeel, P.; Van Boxclaer, J.; De Spiegeleer, B. A new discriminative criterion for the development of Franz diffusion tests for transdermal pharmaceuticals. J. Pharm. Pharm. Sci., 2010, 13(2), 218-30.
49. Zendzian, R.P. Dermal absorption of pesticides in the rat. AIHAJ, 2000, 61(4), 473-483.
50. Collier, S.W.; Sheikh, N.M.; Sakr, A.; Lichtin, J.L.; Stewart, R.F.; Bronaugh, R.L. Maintenance of skin viability during in vitro percutaneous absorption/metabolism studies. Toxicol. Appl. Pharmacol., 1989, 99(3), 522-533.
51. Bronaugh, R.L. Methods for in vitro skin metabolism studies. Toxicol. Methods, 1995, 5(4), 275-281.
52. Harrison, S.M.; Barry, B.W.; Dugard, P.H. Effects of freezing on human skin permeability. J. Pharm. Pharmacol., 1984, 36(4), 261-262.
53. Swarbrick, J.; Lee, G., Brom, J. Drug permeation through human skin: I. Effect of storage conditions of skin. J. Invest. Dermatol., 1982, 78(1), 63-66.
54. Hawkins, G.S.; Reifenrath, W.G. Development of an in vitro model for determining the fate of chemicals applied to skin. Fundam. Appl. Toxicol. 1984, 4(2), S133-144.
55. Davies, D.J., Ward, R.J., Heylings, J.R. Multi-species assessment of electrical resistance as a skin integrity marker for in vitro percutaneous absorption studies. Toxicol. In Vitro., 2004, 18(3), 351-358.
56. United States Environmental Protection Agency (USEPA). In vitro dermal absorption rate testing of certain chemicals of interest to the Occupational Safety and Health Administration. Final rule. Fed. Regist., 2004, 69(80): 22402-22441.
57. Ursin, C., Hansen, C.M.; Van Dyk, J.W.; Jensen, P.O.; Christensen, I.J.; Ebbehoej, J. Permeability of commercial solvents through living human skin. Am. Ind. Hyg. Assoc. J., 1995, 56(7), 651-660.
58. Baert, B.; Deconinck, E.; Van Gele, M.; Slodicka, M.; Stoppie, P.; Bodé, S.; Slegers, G.; Vander Heyden, Y.; Lambert, J.; Beetens, J.; De Spiegeleer, B. Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds. Bioorg. Med. Chem., 2007, 15(22), 6943-55.
59. Frantz, S.W. In: Methods for skin absorption. Kemppainen, B.W. and Reifenrath, W.G., Eds.; CRC Press: Boca Raton, 1990; pp. 35-61.
60. Scott, R.C.; Batten, P.L.; Clowes, H.M.; Jones, B.K.; Ramsey, J.D. Further validation of an in vitro method to reduce the need for in vivo studies for measuring the absorption of chemicals through rat skin. Fundam. Appl. Toxicol., 1992, 19(4), 484-492.
61. Zhai, H.; Maibach, H.I. Effects of skin occlusion on percutaneous absorption: an overview. Skin Pharmacol. Appl. Skin Physiol., 2001, 14(1), 1-10.
62. Chilcott, R.P.; Jenner, J.; Hotchkiss, S.A.; Rice, P. Evaluation of Barrier Creams against Sulphur Mustard I. In vitro Studies Using Human Skin. Skin Pharmacol. Appl. Skin Physiol., 2002, 15(4), 225-235.
63. Guy, R.H. Iontophoresis-recent developments. J. Pharm. Pharmacol., 1998, 50(4), 371-374.
64. Vanbever, R.; Pliquett, U.F.; Préat, V.; Weaver, J.C. Comparison of the effects of short, high-voltage and long, medium-voltage pulses on skin electrical and transport properties. J. Control. Release., 1999, 60(1), 35-47.
65. Barry, B.W. In: Percutaneous penetration enhancers. Smith, E.W. and Maibach, H.I., Eds.; CRC Press: Boca Raton, 2006; pp. 3-16.
66. Aungst, B.J. Absorption Enhancers: Applications and Advances. AAPS J., 2011, DOI: 10.1208/s12248-011-9307-4, 1-9.
67. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev., 2004, 56(5), 603-618.
68. Hope, M.J.; Kitson, C.N. Liposomes. A perspective for dermatologists. Dermatol. Clin., 1993, 11(1), 143-154.
69. Vávrová, K.; Zbytovská, J.; Hrabálek, A. Amphiphilic transdermal permeation enhancers: structure-activity relationships. Curr. Med. Chem., 2005, 12(19), 2273-91.
70. Novotný, M.; Klimentová, J.; Janůšová, B.; Palát, K.; Hrabálek, A.; Vávrová, K. Ammonium carbamates as highly active transdermal permeation enhancers with a dual mechanism of action. J. Control. Release, 2011, 150(2), 164-70.